Last reviewed · How we verify
NCT04662892: POEM
An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
trial testing Pegfilgrastim-Cbqv in Febrile Neutropenia in 200 participants. Status unknown.
1 November 2022
Quick facts
| Lead sponsor | Coherus Oncology, Inc. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 August 2020 |
| Primary completion | 1 November 2022 |
| Estimated completion | 15 December 2022 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Pegfilgrastim-Cbqv — full drug profile →
Conditions studied
- Febrile Neutropenia — all drugs for Febrile Neutropenia →
- Non-myeloid Malignancy — all drugs for Non-myeloid Malignancy →
Sponsor
Coherus Oncology, Inc. — full company profile →
Who can join
18 and older, any sex, with Febrile Neutropenia or Non-myeloid Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, prospective, observational cohort registry in subjects receiving myelosuppressive chemotherapy for a non-myeloid malignancy who are considered to be at high risk for developing febrile neutropenia (FN).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04662892
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Febrile Neutropenia
Currently open trials in the same condition.
- NCT07204522 — Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients. · recruiting
- NCT05815628 — Next-Generation-Sequencing Approach to Neutropenic Sepsis · recruiting
- NCT06787326 — Effect of the BioFire FilmArray (BCID2) for the Rapid Detection of Bloodstream Infection in Haematologic Patients With F · active not recruiting
- NCT05786495 — Short Antibiotic Treatment in High Risk Febrile Neutropenia · NA · recruiting
Other Coherus Oncology, Inc. trials
Trials by the same sponsor.
- NCT06389526 — A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors · Phase 1 · not yet recruiting
- NCT05757492 — Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors · Phase 1 · terminated
- NCT05635643 — Study of CHS-114 in Participants With Advanced Solid Tumors · Phase 1 · recruiting
- NCT05359861 — Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma · Phase 2 · completed
- NCT05177770 — Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Pros · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04662892 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Coherus Oncology, Inc.
- Last refreshed: 23 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04662892.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing